To outline key evidence-based guidelines and trials that inform infectious disease care.
Approach:
IDSA Antimicrobial-Resistant Gram-Negative Guidance: Addresses treatment of infections caused by extended-spectrum beta-lactamase–producing Enterobacterales, AmpC beta-lactamase–producing Enterobacterales, carbapenem-resistant Enterobacterales, difficult-to-treat Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia.
IDSA COVID-19 Treatment Guideline Update: Includes nine revised recommendations on COVID-19 treatments based on a systematic review of the literature, including guidance on antiviral selection.
CDC Doxycycline Postexposure Prophylaxis Guideline: Recommends doxycycline for preventing bacterial STIs in men who have sex with men and transgender women after exposure.
HIV Medicine Association and IDSA Primary Care Guidance: Covers comprehensive primary care for HIV patients, including therapy access, preventive care, and management of comorbidities.
DoxyPEP Trial: Demonstrated lower rates of gonorrhea, chlamydia, and syphilis with doxycycline postexposure prophylaxis in men who have sex with men and transgender women.
CENTERSTONE Trial: Showed lower influenza transmission with baloxavir marboxil compared to placebo in a phase 3b trial.
CERTAIN-1 Trial: Cefepime-taniborbactam showed higher success rates in treating complicated urinary tract infections compared to meropenem.
Lenacapavir for HIV Preexposure Prophylaxis: Identified as an option for HIV prevention based on trial data demonstrating reduced HIV incidence.
Key Findings:
IDSA guidelines provide comprehensive treatment strategies for resistant infections.
COVID-19 treatment recommendations are based on systematic reviews.
Doxycycline postexposure prophylaxis is effective in preventing STIs in specific populations.
New HIV prevention options have been approved based on clinical trial data.
Interpretation:
The framework reflects essential guidelines and trial data that inform clinical practice in infectious diseases.
Conclusion:
The article summarizes critical evidence-based resources for managing infectious diseases.
